Trial Profile

A third Phase 2B study for the take-home use of MB22001

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lysergic acid diethylamide MindBio Therapeutics (Primary)
Indications Major depressive disorder
Focus Adverse reactions; Therapeutic Use

Most Recent Events

07 May 2024 New trial record
01 May 2024 According to a MindBio Therapeutics media release, company is now running a third Phase 2B trial that has now also been approved in women's health.
01 May 2024 According to a MindBio Therapeutics media release, company expects the results of this Phase 2B trials to be announced in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com